Testing two drug combinations for rare bladder cancer

This trial is testing a medication called lurbinectedin to treat a very rare and aggressive bladder cancer called small cell carcinoma of the bladder, or similar rare cancers of the urinary tract. You would receive either lurbinectedin alone, or lurbinectedin combined with another medication called avelumab that helps your immune system fight cancer. The goal is to see how well this medication works and how tolerable it is for patients.

This type of bladder cancer is extremely rare and very aggressive, and current standard treatments often stop working quickly. There is limited guidance on what to do when the cancer progresses or comes back. This trial is testing a new medication to give patients more effective treatment options.